Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adenovirus may cause heart transplant rejection:

This article was originally published in Clinica

Executive Summary

Rejection of heart transplants, at least in children, may be linked to adenoviral infection, a US team has concluded. Researchers from Baylor College of Medicine in Houston, Texas, and other research institutions, report in The New England Journal of Medicine (May 17) that PCR analysis detected viral DNA in endomyocardial biopsy specimens from 34 out of 149 transplant recipients aged up to 18 years. Some 29 (85%) of these patients had an adverse cardiac event within three months of the biopsy, in contrast to only 39 of the 115 (34%) with negative PCR findings. Adenovirus was found three times as often as the next most common virus, enterovirus. The finding suggests that all heart transplant patients should be routinely screened for viral DNA, the researchers say.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT071376

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel